Cigarette smoking is the most significant single cause of illness and premature death globally. Worldwide, tobacco kills 7 million people every year. Almost a million deaths are due to non-smokers being exposed to second-hand smoke. Smoking cessation is the process of ceasing tobacco smoking. It is among one of the dynamic markets and is expected for exponential growth despite the economic conditions. Both prescription and over-the-counter products are available in the market.
The key drivers of the smoking cessation market include increasing tobacco consumption population, awareness amongst smokers on hazards of smoking, banning of tobacco product advertisement in many countries. Strict governmental regulations are emphasized to control the toxic effects on cardiac and respiratory systems. As a step forward, smoking is banned in public places, and high taxes are implemented on tobacco products and massive support to the cessation therapies. The major challenge faced by the market is the side effects of the drugs.
The market of smoking cessation is segmented based on various factors like product type, geography, end-users. Based on cessation aids, it is split by type NRT inhaler, NRT patch, spray, drug electronic cigarettes. Based on end-user, the market is segmented by application pharmacy, supermarket, hospital, other. Based on region, it is segmented as North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, Europe, Middle East & Africa. Due to increased awareness and government programs, APAC can be predicted as a profitable market.
In spite of available OTC and prescribed products, a robust pipeline of drugs is developed by several vendors. Monotherapy products that are already in the market are tested for combination therapy to reach better and rapid therapeutic targets.
Some of the products in the pipeline include X-22 Smoking Cessation Product of 22nd Century Limited is in phase 2; SELA-070, SEL-068 of Selecta Biosciences, Inc., is in phase 1 clinical trials. Despite failed results, unique products such as vaccines are also being investigated by researchers to curb smoking addiction.
Some of the key players include Reckitt Benckiser, Pfizer, GlaxoSmithKline, Roche, Novartis, Johnson and Johnson, Bayer, Cipla, Takeda Pharmaceuticals, Sanofi, Selecta Biosciences, 22nd Century Limited, Fertin Pharma, Achieve Life Sciences, McNeil AB.